These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29226734)

  • 1. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
    Jamy O; Sonpavde G
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatments for metastatic urothelial carcinoma.
    Lalani AA; Sonpavde GP
    Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel for the treatment of bladder cancer.
    Albany C; Sonpavde G
    Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
    Aragon-Ching JB; Trump DL
    Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Meeks JJ; Black PC; Galsky M; Grivas P; Hahn NM; Hussain SA; Milowsky MI; Steinberg GD; Svatek RS; Rosenberg JE
    Eur Urol; 2023 Nov; 84(5):473-483. PubMed ID: 37258363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advanced bladder cancer : From chemo- to immunotherapy].
    Horn T; Krege S; Retz M
    Urologe A; 2018 Jun; 57(6):686-692. PubMed ID: 29637216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
    Todenhöfer T; Boegemann M
    Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
    Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.